This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
What’s more, synthesized Delta-9 THC is present in many of these products, despite being prohibited in both California’s cannabis and hemp programs. In response to its growing popularity, the DEA announced in 2016 that kratom would be placed in the restrictive Schedule I along with cannabis. “The market crashed.
Small Business Administration (SBA) has quietly reintroduced a policy that effectively disqualifies most of them from critical federal loan programs. SBA policy timeline: A whiplash-inducing history The SBAs latest update to its 7(a) and 504 loan programs represents a return to the more restrictive, 2020 policy.
Lykos’ application to the FDA cited two late-stage clinical trials (MAPP1, 2021, and MAPP2, 2023) published in Nature Medicine in which approximately 200 participants diagnosed with PTSD were randomly assigned to receive either MDMA or a placebo. This raised concerns about the oversight and ethical safeguards within Lykos’s research program.
SOUTH DAKOTA Has South Dakota’s medical cannabis program been too successful? Some lawmakers, concerned that the 12,000 cards issued by the state’s MMJ program is nearly double original projections, are calling for closer monitoring of the process. Proposed rules for the program could be introduced in the legislature later this year.
This legislation would decriminalize marijuana use at the federal level, require expungement of criminal records and set up grant programs for those most affected by the War on Drugs. Senator Raphael Warnock (D-GA) DEA ACT Another cannabis act was introduced late last week, the Deferring Executive Authority Act (DEA).
The DEA sends a letter to Georgia pharmacies. Well, apparently the Drug Enforcement Administration (DEA) noted that as well, and they didn’t take kindly to it. But wait, isn’t there a provision that prohibits the Department of Justice (of which DEA is a part) from interfering with state legal medical marijuana programs?
We thought the market would expand “quite a bit” in 2023 – well, the “a bit” part was right. And not to ruin the ending, but no retail market will open in 2023. As of now, this is still a proposal, and it’s anyone’s guess if the DEA (who would do the actual re-scheduling) will think that’s a good idea. by a large margin.
We note that New York’s cannabis licensing program is facing yet another lawsuit. UNITED STATES ATTORNEYS Attorney General Merrick Garland and DEA Administrator Anne Milgram received a letter this week from several former United States Attorneys. And we check in on Virginia – how’s that retail market coming along?
Cannabinoid Hemp Program Regulations (Finally) Finalized. While much attention is focused on New York’s adult-use cannabis market, the CCB and Office of Cannabis Management (OCM) are also responsible for overseeing both the Medical Marijuana and Cannabinoid Hemp Programs.
An Examination of the USDA Hemp Production Program. Hemp Roundtable Vice President and CEO of Kentucky-based Ecofibre, Eric Wang, testified alongside Kentucky Commissioner of Agriculture, Ryan Quarles, during a Congressional hearing regarding “ An Examination of the USDA’s Hemp Production Program.” Washington D.C.
MDMA is a promising psychedelic compound, currently placed by the Drug Enforcement Administration (DEA) in Schedule I of the Controlled Substances Act, that has been produced for legal research in small batches by certified laboratories. Berra Yazar-Klosinski, Ph.D. contributing author and MAPS PBC Chief Scientific Officer.
It was officially listed on the NYSE in August and granted a DEA schedule I manufacturing license in November. Headed by two-time entrepreneur of the year Kelsey Ramsden , one of Mind Cure’s primary focuses is its digital therapeutics program, iSTRYM. Also in November, it reported positive data on its standout IND, CYB003.
“We’re continuing to drive cost savings and operational efficiencies across the company, and remain broadly on track to our target of $150 – $200 million in fiscal 2022- fiscal 2023,” added Mike Lee , CFO. “We Drug Enforcement Administration (the “DEA”), the U.S. First Quarter Fiscal 2022 Financial Summary. hemp industry in the U.S.,
“Our cost savings program is on track to deliver $150 – $200 million of savings within the next 18 months, and we remain committed to our path to profitability by the end of Fiscal 2022, while continuing to invest in an organization that is focused on insights, innovation and gaining momentum in the U.S.
cannabis community awaits the resumption of the DEA’s administrative law hearing on rescheduling marijuana later this month, this blog will take a glimpse at the ever-dynamic global landscape of cannabis policy. Phase I, implemented in 2023, legalized cannabis cultivation clubs, home cultivation, and personal possession.
Schedule III substances are subject to certain controls not applicable to all other prescription drugs, including the requirement that a medical professional with a specific license issued by the Drug Enforcement Agency (DEA) must conduct an in-person examination before prescribing it. At-home ketamine treatment programs vary.
Before the 2018 Farm Bill, only a few states ran limited “research” pilot programs for hemp. This ties directly into marijuana policy, the Controlled Substances Act, and what DEA is thinking about. This would moot the problematic DEA rule referenced above, which was upheld by the D.C Could that be true? Court of Appeals agreed.
Both Oregon and California (and now Washington) have THC program export bills, but those laws are anticipatory and mostly symbolic. Neither California nor Washington – nor any other state with a closed-loop, “marijuana” program – allows for licensee shipments interstate. The 2018 Farm Bill is set to expire September 30, 2023.
Earlier this year, we wrote about how MAPS was progressing through the Phase III study process and was targeting FDA approval in 2022 and commercialization in 2023 — if these targets are met, they would be on par with Oregon’s legal psilocybin licensing program.
8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. 9] Experts predict that this therapy could receive full FDA approval as soon as 2023. [10] DEA and the Controlled Substances Act. Under the Controlled Substances Act of 1970, DEA classifies drugs into one of five schedules.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content